GlaxoSmithKline announced that alli (orlistat) 60mg capsules have returned to most stores in the United States and Puerto Rico following the voluntary recall in March 2014.
The recall was issued after it was determined that some packages did not contain genuine alli capsules. The product tampering appeared to result after the affect product was shipped to retail outlets.
alli is a lipase inhibitor approved as adjunct to a reduced-calorie, low-fat diet for weight loss in overweight adults. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine residue site of gastric and 10 pancreatic lipases. As undigested triglycerides are not absorbed, the resulting caloric deficit may have a positive effect on weight control.
For more information call (888) 825-5249 or visit MyAlli.com.
This article originally appeared on MPR